Cipla has received the Establishment Inspection Report (EIR), indicating closure of the inspection from United States Food and Drug Administration (USFDA). The agency had conducted inspection at API manufacturing facility in Virgonagar, Bengaluru, from July 15-19, 2019.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
